Close Menu

Wadsworth Center

The first year's pilot phase aimed to develop an infectious disease digital health and precision medicine platform connecting healthcare facilities to NYSDOH.

Wadsworth's test detects antibodies against SARS-CoV-2 in serum, while Altru Diagnostics' test detects viral nucleic acid in respiratory specimens.

Core labs remain closed or at reduced operations due to the COVID-19 pandemic, leading to concerns about the state of their businesses when they can reopen.

Despite the astronomical costs, it may prove challenging to reverse course and discontinue Zika testing according to a commentary article accompanying a NEJM study.

The assay was developed in the Wadsworth Center Biodefense Laboratory and includes a novel sample prep enabling detection from stool.

The University at Albany this week announced that scientists from its RNA Institute have begun collaborating with researchers from the Wadsworth Center of the New York State Department of Health and Rensselaer Polytechnic Institute to advance new biomedical technologies.

Akonni Biosystems and Albany, NY-based Wadsworth Center are working together under a $300,000 National Institutes of Health grant to develop a closed amplicon PCR microarray to detect encephalitis- and meningitis-causing viruses in cerebral spinal fluid, Akonni said this week.

Agilent Technologies, Columbia University, and others are collaborating on development of the system, which will be based on MassTag PCR.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.